|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
|
30900377 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Using HA10 as an IHC reagent, we found that CD133 is a marker for a very rare cell type in both healthy prostate and adenocarcinoma sections.
|
29790189 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We have demonstrated for the first time high expression of D<sub>2</sub> dopamine (DA) receptors in CD133+ve adenocarcinoma NSCLC cells.
|
27920206 |
2017 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immuno-expression of EpCAM, CD44 and CD133 in cardiac mucosa was significantly lower (mean immunoreactivity score (IRS)=1.2; 0.0; 0.4; respectively) compared to their expression in Barrett's metaplasia (mean IRS=4.3; 0.14; 0.7; respectively), in early adenocarcinoma (mean IRS=4.4; 0.29; 1.3; respectively) and in advanced adenocarcinoma (mean IRS=6.6; 0.7; 2.7; respectively) (p<0.05).
|
28216140 |
2017 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
For all CRC patients, positive LGR5 mRNA and CD133 expression were associated with classic adenocarcinoma histology type (p = 0.001 and p = 0.014, respectively).
|
27435662 |
2016 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The CD44 and CD133 mRNA levels in 36 primary colorectal adenocarcinomas with synchronous hepatic metastasis were analyzed by reverse transcriptase polymerase chain reaction, with normalization relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
|
25625240 |
2015 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Furthermore, in the 200 lung cancer and the matched normal tissues, PROM1 mutation occurred in 3 patients (i.e., one squamous cell carcinoma and two adenocarcinomas) with a mutation frequency of 1.5%, while CRTC2 mutation occurred in 5 patients (two squamous cell carcinomas and three adenocarcinomas) with a mutation frequency of 2.5%.
|
24484648 |
2014 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We examined 45 matched primary/recurrent tumor pairs of high-grade ovarian adenocarcinomas for expression of CSC markers ALDH1A1, CD44, and CD133 using immunohistochemistry.
|
22142828 |
2012 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B7-H3 expression in squamous cell carcinoma (SCC) was significantly higher than those in adenocarcinoma (p=0.048), while CD133 expression in large cell lung carcinoma was higher than that in SCC (p=0.023).
|
20844808 |
2010 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The CD133 mRNA levels in 61 primary colorectal adenocarcinomas were analyzed by reverse transcriptase-polymerase chain reaction, with normalization relative to GAPDH.
|
20872808 |
2010 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
These signaling molecules were also present in the bulk tumor mass of CD133(-) prostate cancer cells with a luminal phenotype detected in patient's adenocarcinoma tissues.
|
20179163 |
2010 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, CD133+CD44+ cells in the adenocarcinoma cell line A549 have expressive significant cancer stem cell properties with continuous proliferative capacity and differentiation potential.
|
20937222 |
2010 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results have revealed that MUC4 mucin is overexpressed in CD133(+) and CD133(-) pancreatic cells (PCs) detected in patient's adenocarcinoma tissues while no significant expression was seen in normal pancreatic tissues.
|
20303649 |
2010 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
LHGDN |
All 21 tumors with CD133 overexpression were diagnosed as well- or moderately-differentiated adenocarcinoma.
|
18754869 |
2008 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
All 21 tumors with CD133 overexpression were diagnosed as well- or moderately-differentiated adenocarcinoma.
|
18754869 |
2008 |